Psychopharmacology: A Master Class

Charles Nemeroff, MD, PhD

August 20 – 24, 2018 • Monday – Friday

See Accreditation

REGISTER NOW

This seminar will begin with an updated review of neurobiology ranging from neurotransmitters to neuroendocrinology to imaging. The seminal role of child abuse and neglect in increased vulnerability to mood and anxiety disorders will be explored with a focus on the long term persistent effects of early life trauma on the brain. An update on the pathophysiology of the major psychiatric disorders will be described including new data on inflammation. The latest data on suicide will be presented including risk factors and strategies for prevention.

 

Treatment of schizophrenia, bipolar disorder, depression, anxiety, and women’s psychiatric disorders will be described. The evidence-based effectiveness of antipsychotic medications will be emphasized in psychotic disorders and as augmenting agents in major depression. Newer agents and augmenting medications for the treatment of mood disorders will be discussed with an emphasis on treatment-resistant depression. Bipolar disorder and its treatment will be examined with particular emphasis on bipolar depression. The use of lithium as the gold standard of treatment will be emphasized. A comprehensive review of primary depression as well as depression co-morbid with medical illnesses will be highlighted, particularly the role of depression in cardiovascular illness and the necessity for treatment.

 

The neurobiological mechanisms of anxiety and anxiety-spectrum disorders as well as their treatment will be reviewed, including obsessive-compulsive disorder, panic disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), and generalized anxiety disorder. Medications for depression in women through the course of their lifecycle will be presented.

 

Advances in personalized or precision medicine will be a major focus of the course including both pharmacotherapy and psychotherapy.

 

The course will emphasize the establishment and importance of the therapeutic alliance when prescribing all psychotropic medications.

 

Upon completion of this seminar, participants will be able to:

 

  • Apply the latest advances in the neurobiology of psychiatric disorders and the role of genetic testing in the selection of specific psychiatric medications;
  • Evaluate the mechanisms of action of psychotropic drug treatment;
  • Assess and compare current mechanisms and latest treatment of psychotic disorders, schizophrenia and bipolar illness;
  • Analyze and assess the neurobiological mechanism and evidence-based treatment of depressive and anxiety-spectrum disorders;
  • Review latest findings about inflammation and stress as they apply to the treatment of depression and anxiety-spectrum disorders;
  • Review the data on risk factors for suicide and suicide presentation strategies;
  • Analyze the role of psychopharmacology in the treatment of generalized anxiety disorder, obsessive symptoms, panic symptoms, and traumatic syndromes;
  • Describe the interaction between psychiatric and medical illnesses;
  • Review the preeminent role of child abuse and neglect on risk for mood and anxiety disorders;
  • Update the clinical approach to problems in geriatric psychopharmacology with emphasis on newly emerging medication treatment;
  • Make dosage adjustments in the elderly for age, drug interactions, and sensitivity to side effects;
  • Review the use of psychiatric medications during a women’s life cycle: pregnancy, delivery, postpartum, nursing, and menopause.

 

SCHEDULE

 

Monday August 20, 2018

8:30-9:00 am

Registration

9:00- 10:15 am

An updated and clinically relevant review of neurobiology as it applies to the etiology and pathophysiology of psychiatric illness, and psychotropic drug treatment effects.

10:15-10:30 am

Coffee Break

10:30-12:15pm

The neurobiology of child abuse and neglect and implications for the course and treatment of mood and anxiety disorders. Q & A

Tuesday, August 21, 2018

9:00-10:15 am

The epidemiology and neurobiology of suicide; suicide prevention strategies Biology and treatment of bipolar disorder; current standards of practice; special emphasis on evidence-based treatments of bipolar depression; Q&A.

10:15-10:30 am

Coffee Break

10:30-12:15 pm

Continue- The epidemiology and neurobiology of suicide; suicide prevention strategies Biology and treatment of bipolar disorder; current standards of practice; special emphasis on evidence-based treatments of bipolar depression; Q&A.

Wednesday, August 22, 2017

9:00-10:15 am

Personalized medicine in psychiatry.

10:15- 10:30 am

Coffee Break

10:30-12:15 pm

The biology, epidemiology, and treatment of PTSD; Q & A.

Thursday, August 23, 2018

9:00-10:15 am

The role of inflammation in the pathophysiology of mood disorders.

10:15-10:30 am

Coffee Break

10:30-12:15pm

Management of treatment resistant depression with a focus on psychopharmacological treatments; review of STAR*D study and other evidenced based clinical trials; Q&A.

Friday, August 24, 2018

9:00-10:15 am

Mood disorders in women including premenstrual syndrome, pregnancy, lactation, and postpartum depression.

10:15-10:30  am

Coffee Break

10:30-12:15 pm

Presentation of interesting/difficult cases from attendee’s practice for discussion and review; Q&A.

12:15 pm

Course Adjourn